Note: Descriptions are shown in the official language in which they were submitted.
CA 02980327 2017-09-19
WO 2016/154584 PCT/US2016/024319
ALIGNMENT AND VARIANT SEQUENCING ANALYSIS PIPELINE
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims priority to and the benefit of U.S.
Provisional Application
Nos. 62/138620, filed March 26, 2015, and 62/253908, filed November 11, 2015,
the contents
of which are each incorporated herein by reference in their entirety.
BACKGROUND
[0002] Every year, more than 200,000 new cases of breast cancer are
diagnosed in the
United States. Of these, approximately 2% to 5% are associated with loss-of-
function variants
in the BRCA1 or BRCA2 genes. With the exception of Ashkenazi-Jewish women, who
have a
2% to 5% carrier frequency for 3 founder mutations in BRCA1 and BRCA2, the
estimated
carrier frequency in the general population is 1:300 for BRCA1 and 1:800 for
BRCA2. Patients
with deleterious mutations in either the BRCA1 or BRCA2 gene have a 50% to 80%
lifetime
risk of developing breast cancer and a 20% to 40% lifetime risk of developing
ovarian cancer.
Triple-negative breast cancers¨those that do not express estrogen receptor,
progesterone
receptor, or Her2/neu and are characterized as being more aggressive¨account
for 15% to 20%
of all breast cancers; they are associated with BRCA mutations at frequencies
between 4% and
42%, depending on the characteristics of the study population (e.g.,
proportion of women who
are Ashkenazi Jewish).
[0003] The National Comprehensive Cancer Network (NCCN) has developed
guidelines for
assisting healthcare providers in identifying patients and family members at
high risk of breast
and ovarian cancer and who may benefit from cancer genetic risk assessment.
Genetic risk
assessment can include genetic testing but is a dynamic counseling process.
Determining
whether a woman with breast cancer is BRCA1/2 positive can assist in
appropriate counseling
regarding increased surveillance and the risks and benefits of undergoing
contralateral
mastectomy and/or salpingo-oophorectomy, both of which have been shown to be
protective
against breast cancer. Identifying a deleterious BRCA1/2 variant in a patient
can also be helpful
to family members, who may need access to genetic counseling and testing to
assess their
cancer risk and identify appropriate management. The American Society of
Breast Surgeons
- 1 -
CA 02980327 2017-09-19
WO 2016/154584 PCT/US2016/024319
recommends BRCA1/2 testing for individuals from high-risk populations,
including those with
early onset breast cancer (diagnosed before age 50); two primary breast
cancers, either bilateral
or ipsilateral; family history of early onset breast cancer; male breast
cancer; personal or family
history of ovarian cancer (particularly nonmucinous types); Ashkenazi (Eastern
European)
Jewish heritage in the setting of a newly diagnosed breast cancer or family
history of breast
cancer; previously identified BRCA1 or BRCA2 mutation in the family; triple-
negative breast
cancer at <60 years of age; or pancreatic cancer associated with a family
history of hereditary
breast and ovarian related cancer.
[0004] Comprehensive BRCA testing typically consists of sequencing all the
coding exons
and the splice junction regions of BRCA1 and BRCA2 and analysis of large gene
rearrangements. PCR-based sequencing methods, including Sanger sequencing and
next-
generation sequencing (NGS) systems that use PCR amplification, may yield
false-negative
results due to allele drop-out when polymorphisms are present in amplification
or sequencing
primer sequences.
[0005] Accordingly, there is a need for improved methods for sequencing
samples and
methods for accurate and efficient analysis of NGS sequencing data.
SUMMARY
[0006] Provided herein in certain embodiments are methods of processing
sequencing data
generated by high throughput sequencing methods, including next generation
sequencing
platforms. Exemplary sequencing platforms include, but are not limited to,
Illumina MiSeq
System and the Life Technologies Ion Torrent Personal Genome Machine.
[0007] Provided herein, in certain embodiments, are methods for determining
the presence
of a variant in one or more genes in a subj ect comprising: (a) providing raw
sequencing data
generated from a nucleic acid sequencing reaction on a nucleic acid sample
from the subject
using a nucleic acid sequencer; (b) removing low quality reads from the raw
sequencing data
that fail a quality filter; (c) trimming adapter and/or molecular
identification (MID) sequences
from the filtered raw sequencing data; (d) mapping the filtered raw sequencing
data to a
genomic reference sequence to generate mapped reads; (e) sorting and indexing
the mapped
reads; (f) adding read groups to a data file to generate a processed sequence
file; (g) creating
- 2 -
CA 02980327 2017-09-19
WO 2016/154584 PCT/US2016/024319
realigner targets; (h) performing local realignment of the processed sequence
file to generate a
re-aligned sequence file; (i) removing of duplicate reads from the re-aligned
sequence file; (j)
analyzing coding regions of interest; and (k) generating a report that
identifies whether the
variant is present based on the analysis in step (j), wherein steps (g) and
(j) are performed using
a modified genomic alignment utility limited to nucleic acid regions
containing the one or more
genes of interest. In some embodiments, the method comprises performing the
nucleic acid
sequencing reaction on the nucleic acid sample from the subject using a
nucleic acid sequencer
to generate the raw sequencing data of step (a). In some embodiments,
analyzing coding regions
of interest comprises calling variants at every position in the regions of
interest. In some
embodiments, the regions of interest are padded by an additional 150 bases. In
some
embodiments, variant calling is performed with a modified GATK variant caller.
In some
embodiments, mapping the reads to a genomic reference sequence is performed
with a Burrows
Wheeler Aligner (BWA). In some embodiments, mapping the reads to a genomic
reference
sequence does not comprise soft clipping. In some embodiments, the genomic
reference
sequence is GRCh37.1 human genome reference. In some embodiments, the
sequencing
method comprises emulsion PCR (emPCR), rolling circle amplification, or solid-
phase
amplification. In some embodiments, the solid-phase amplification is clonal
bridge
amplification.
[0008] In some embodiments, the nucleic acid for sequence analysis is
extracted from a
biological sample from a subject. In some embodiments, the biological sample
is a fluid or
tissue sample. In some embodiments, the biological sample is a blood sample.
In some
embodiments, the nucleic acid is genomic DNA. In some embodiments, the nucleic
acid is
cDNA reversed transcribed from mRNA.
[0009] In some embodiments, wherein the nucleic acid samples is prepared
prior to
sequencing by performing one or more of the following methods: (a) shearing
the nucleic acid;
(b) concentrating the nucleic acid sample; (c) size selecting the nucleic acid
molecule in a
sheared nucleic acid sample; (d) repairing ends of the nucleic acid molecules
in the sample
using a DNA polymerase; (e) attaching one or more adapter sequences; (f)
amplifying nucleic
acids to increase the proportion of nucleic acids having an attached adapter
sequence; (g)
enriching the nucleic acid sample for one or more genes of interest; and/or
(h) quantification of
- 3 -
CA 02980327 2017-09-19
WO 2016/154584 PCT/US2016/024319
the nucleic acid sample primer immediately prior to sequencing. In some
embodiments, the one
or more adapter sequences comprises nucleic acid sequences for priming the
sequencing
reaction and/or a nucleic acid amplification reaction. In some embodiments,
the one or more
adapter sequences comprises a molecular identification (MID) tag. In some
embodiments,
enriching the nucleic acid sample for one or more genes of interest comprises
exon capture
using one or more biotinylated RNA baits. In some embodiments, the
biotinylated RNA baits
are specific for exonic regions, splice junction sites, or intronic region or
one or more genes of
interest. In some embodiments, the one or more biotinylated RNA baits are
specific for a
BRCA1 gene and/or a BRCA2 gene.
[0010] In some embodiments, the nucleic acid for sequence analysis is
obtained from a
subject that is a mammal. In some embodiments, the subject is a human patient.
In some
embodiments, the subject is a human suspected of having cancer or suspected of
being at risk of
developing a cancer. In some embodiments, the cancer is a breast or ovarian
cancer.
[0011] In some embodiments, one or more variants in a gene associated with
a cancer are
determined by the methods provided herein. In some embodiments, one or more
variants in the
BRCA1 gene or BRCA2 gene are determined. In some embodiments, one or more
variants is
selected from the variants listed in Table 1.
[0012] In some embodiments, the methods provided further comprise
confirming the
presence of the one or more variants by sequencing.
[0013] Also provided herein, in certain embodiments, are systems comprising
one or more
electronic processors configured to: (a) remove low quality reads from the raw
sequencing data
that fail a quality filter; (b) trim adapter and/or molecular identification
(MID) sequences from
the filtered raw sequencing data; (c) map the filtered raw sequencing data to
a genomic
reference sequence to generate mapped reads; (d) sort and index the mapped
reads; (e) add read
groups to a data file to generate a processed sequence file; (f) create
realigner targets; (g)
perform local realignment of the processed sequence file to generate a re-
aligned sequence file;
(h) remove of duplicate reads from the re-aligned sequence file; and (i)
analyze coding regions
of interest. In some embodiments, analyzing coding regions of interest
comprises calling
variants at every position in the regions of interest. In some embodiments,
the regions of
- 4 -
CA 02980327 2017-09-19
WO 2016/154584 PCT/US2016/024319
interest are padded by an additional 150 bases. In some embodiments, variant
calling is
performed with a modified GATK variant caller. In some embodiments, mapping
the reads to a
genomic reference sequence is performed with a Burrows Wheeler Aligner (BWA).
In some
embodiments, mapping the reads to a genomic reference sequence does not
comprise soft
clipping. In some embodiments, the genomic reference sequence is GRCh37.1
human genome
reference.
[0014] Also provided herein, in certain embodiments, are non-transitory
computer-readable
media having instructions stored thereon, the instructions comprising: (a)
instructions to remove
low quality reads that fail a quality filter; (b) instructions to trim adapter
and MID sequences
from the filtered raw sequencing data; (c) instructions to map the filtered
raw sequencing data
to a genomic reference sequence to generate mapped reads; (d) instructions to
sort and index the
mapped reads; (e) instructions to add read groups to a data file to generate a
processed sequence
file; (f) instructions to create realigner targets; (g) instructions to
perform local realignment of
the processed sequence file to generate a re-aligned sequence file; (h)
instructions to remove
duplicate reads from the re-aligned sequence file; and (i) instructions to
analyze coding regions
of interest. In some embodiments, analyzing coding regions of interest
comprises calling
variants at every position in the regions of interest. In some embodiments,
the regions of
interest are padded by an additional 150 bases. In some embodiments, variant
calling is
performed with a modified GATK variant caller. In some embodiments, mapping
the reads to a
genomic reference sequence is performed with a Burrows Wheeler Aligner (BWA).
In some
embodiments, mapping the reads to a genomic reference sequence does not
comprise soft
clipping. In some embodiments, the genomic reference sequence is GRCh37.1
human genome
reference.
[0015] The foregoing summary is illustrative only and is not intended to be
in any way
limiting. In addition to the illustrative aspects, implementations, and
features described above,
further aspects, implementations, and features will become apparent by
reference to the
following drawings and the detailed description.
- 5 -
CA 02980327 2017-09-19
WO 2016/154584 PCT/US2016/024319
BRIEF DESCRIPTION OF THE DRAWINGS
[0016] The foregoing and other features of the present disclosure will
become more fully
apparent from the following description and appended claims, taken in
conjunction with the
accompanying drawings. Understanding that these drawings depict only several
implementations in accordance with the disclosure and are, therefore, not to
be considered
limiting of its scope, the disclosure will be described with additional
specificity and detail
through use of the accompanying drawings.
[0017] FIG. 1 illustrates an exemplary general overview of the NGS assay
for detection of
BRCA/ and BRCA2 variants in accordance with various illustrative
implementations using the
MiSeq and the Personal Gene Machine (PGM) platforms. For the MiSeq platform,
variant
calling was performed initially with the vendor-supplied MiSeq Reporter
software and then
with the Quest Sequencing Analysis Pipeline (QSAP). For the PGM platform, the
vendor-
supplied Torrent Suite variant-calling software was used.
[0018] FIG. 2 is a flow diagram of the QSAP bioinformatics sequence
analysis methods in
accordance with various illustrative implementations.
[0019] FIG. 3 shows an exemplary alignment of a 40-bp deletion in BRCA1
(deletion
c.1175 1214de140) in a validation sample. The Integrative Genomics Viewer
(IGV) graphic
report shows detection of the mutation with the PGM platform with Torrent
Suite variant
calling (panel A) but not the MiSeq platform with MiSeq Reporter (panel B).
Use of QSAP
with the MiSeq platform allowed detection of the deletion (panel C).
[0020] FIG. 4 shows an exemplary alignment of a 64 bp-deletion (41246533-
41246596de1;
c.952 1015del) in a validation sample. The Integrative Genomics Viewer (IGV)
graphic reports
show detection of the deletion using MiSeq platform with QSAP (panel A) but
not the PGM
platform with Torrent Suite variant calling software (panel B).
[0021] FIG. 5 shows an exemplary determination of cis vs. trans orientation
using next-
generation sequencing (NGS). The Integrative Genomics Viewer (IGV) graphic
report is from a
patient with 2 adjacent variants on a single DNA molecule visualized with NGS
on the
- 6 -
CA 02980327 2017-09-19
WO 2016/154584 PCT/US2016/024319
Mi Seq/QSAP platform. The cis orientation is clearly visible, as each strand
contains either both
or neither of the mutations.
[0022] FIG. 6 is a diagram of a computing system that may be used in
conjunction with the
methods provided herein.
[0023] Reference is made to the accompanying drawings throughout the
following detailed
description. In the drawings, similar symbols typically identify similar
components, unless
context dictates otherwise. The illustrative implementations described in the
detailed
description, drawings, and claims are not meant to be limiting. Other
implementations may be
utilized, and other changes may be made, without departing from the spirit or
scope of the
subject matter presented here. It will be readily understood that the aspects
of the present
disclosure, as generally described herein, and illustrated in the figures, can
be arranged,
substituted, combined, and designed in a wide variety of different
configurations, all of which
are explicitly contemplated and made part of this disclosure.
DETAILED DESCRIPTION
[0024] Certain Terminology
[0025] Certain terms employed in this description have the following
defined meanings.
Terms that are not defined have their art-recognized meanings. That is, unless
otherwise
defined, all technical and scientific terms used herein have the same meaning
as commonly
understood by one of ordinary skill in the art to which this invention
belongs.
[0026] As used herein, unless indicated otherwise, when referring to a
numerical value, the
term "about" means plus or minus 10% of the enumerated value.
[0027] As used herein, the terms "isolated," "purified" or "substantially
purified" refer to
molecules, such as nucleic acid, that are removed from their natural
environment, isolated or
separated, and are at least 60% free, preferably 75% free, and most preferably
90% free from
other components with which they are naturally associated. An isolated
molecule is therefore a
substantially purified molecule.
[0028] A "fragment" in the context of a gene fragment or a chromosome
fragment refers to
a sequence of nucleotide residues which are at least about 10 nucleotides, at
least about 20
- 7 -
CA 02980327 2017-09-19
WO 2016/154584 PCT/US2016/024319
nucleotides, at least about 25 nucleotides, at least about 30 nucleotides, at
least about 40
nucleotides, at least about 50 nucleotides, at least about 100 nucleotides, at
least about 250
nucleotides, at least about 500 nucleotides, at least about 1,000 nucleotides,
at least about 2,000
nucleotides.
[0029] The terms "identity" and "identical" refer to a degree of identity
between sequences.
There may be partial identity or complete identity. A partially identical
sequence is one that is
less than 100% identical to another sequence. Partially identical sequences
may have an overall
identity of at least 70% or at least 75%, at least 80% or at least 85%, or at
least 90% or at least
95%.
[0030] The terms "amplification" or "amplify" as used herein includes
methods for copying
a target nucleic acid, thereby increasing the number of copies of a selected
nucleic acid
sequence. Amplification may be exponential or linear. A target nucleic acid
may be either DNA
or RNA. The sequences amplified in this manner form an "amplification
product," also known
as an "amplicon." While the exemplary methods described hereinafter relate to
amplification
using the polymerase chain reaction (PCR), numerous other methods are known in
the art for
amplification of nucleic acids (e.g., isothermal methods, rolling circle
methods, etc.). The
skilled artisan will understand that these other methods may be used either in
place of, or
together with, PCR methods. See, e.g., Saiki, "Amplification of Genomic DNA"
in PCR
Protocols, Innis et al., Eds., Academic Press, San Diego, CA 1990, pp. 13-20;
Wharamet al.,
Nucleic Acids Res., 29(11):E54-E54, 2001; Hafneret al., Biotechniques,
30(4):852-56, 858,
860, 2001; Zhonget al., Biotechniques, 30(4):852-6, 858, 860, 2001.
[0031] The term "detectable label" as used herein refers to a molecule or a
compound or a
group of molecules or a group of compounds associated with a probe and is used
to identify the
probe hybridized to a genomic nucleic acid or reference nucleic acid.
[0032] As used herein, the term "detecting" refers to observing a signal
from a detectable
label to indicate the presence of a target. More specifically, detecting is
used in the context of
detecting a specific sequence.
[0033] The term "high throughput, massively parallel sequencing" as used
herein refers to
sequencing methods that can generate multiple sequencing reactions of clonally
amplified
molecules and of single nucleic acid molecules in parallel. This allows
increased throughput
- 8 -
CA 02980327 2017-09-19
WO 2016/154584 PCT/US2016/024319
and yield of data. These methods are also known in the art as next generation
sequencing
(NGS) methods. NGS methods include, for example, sequencing-by-synthesis using
reversible
dye terminators, and sequencing-by-ligation. Non-limiting examples of commonly
used NGS
platforms include miRNA BeadArray (I1lumina, Inc.), Roche 454TM GS FLXTM-
Titanium
(Roche Diagnostics), ABI SOLiDTM System (Applied Biosystems, Foster City, CA),
and
HeliScopeTM Sequencing System (Helicos Biosciences Corp., Cambridge MA).
[0034] "Sequencing depth" or "read depth" as used herein refers to the
number of times a
sequence has been sequenced (the depth of sequencing). As an example, read
depth can be
determined by aligning multiple sequencing run results and counting the start
position of reads
in nonoverlapping windows of a certain size (for example, 100 bp). Copy number
variation can
be determined based on read depth using methods known in the art. For example,
using a
method described in Yoon et al., Genome Research 2009 September; 19(9): 1586-
1592; Xie et
al., BMC Bioinformatics 2009 Mar 6; 10:80; or Medvedev et al., Nature Methods
2009 Nov;
6(11 Suppl): S13-20. Use of this type of method and analysis is referred to as
a "read depth
approach."
[0035] A "nucleic acid fragment read" as used herein refers to a single,
short contiguous
information piece or stretch of sequence data. A read may have any suitable
length, for example
a length of between about 30 nucleotides to about 1000 nucleotides. The length
generally
depends on the sequencing technology used for obtaining it. In specific
embodiments, the reads
may also be longer, e.g. 2 to 10 kb or more. The present methods generally
envisage any read or
read length and is not to be understood as being limited to the presently
available read lengths,
but also includes further developments in this area, e.g. the development of
long reading
sequencing approaches etc.
[0036] A "nucleic acid sequence data" as used herein may be any sequence
information on
nucleic acid molecules known to the skilled person. The sequence data can
include information
on DNA or RNA sequences, modified nucleic acids, single strand or duplex
sequences, or
alternatively amino acid sequences, which have to converted into nucleic acid
sequences. The
sequence data may additionally comprise information on the sequencing machine,
date of
acquisition, read length, direction of sequencing, origin of the sequenced
entity, neighboring
sequences or reads, presence of repeats or any other suitable parameter known
to the person
- 9 -
CA 02980327 2017-09-19
WO 2016/154584 PCT/US2016/024319
skilled in the art. The sequence data may be presented in any suitable format,
archive, coding or
document known to the person skilled in the art. The data may, for example, be
in the format of
FASTQ, Qseq, CSFASTA, BED, WIG, EMBL, Phred, GFF, SAM, SRF, SFF or ABI-ABIF.
[0037] The phrase "obtaining sequence data from a plurality of nucleic acid
fragment reads"
as used herein refer to the process of determining the sequence information of
a subject, or a
group of subjects by the performance of nucleic acid sequencing reactions.
[0038] The term "multiplex PCR" as used herein refers to an assay that
provides for
simultaneous amplification and detection of two or more target nucleic acids
within the same
reaction vessel. Each amplification reaction is primed using a distinct primer
pair. In some
embodiments, at least one primer of each primer pair is labeled with a
detectable moiety. In
some embodiments, a multiplex reaction may further include specific probes for
each target
nucleic acid. In some embodiments, the specific probes are detectably labeled
with different
detectable moieties.
[0039] The term "nested polymerase chain reaction" is a modification of
polymerase chain
reaction which, in the present context, is performed to add sequences to an
amplicon. Nested
polymerase chain reaction involves two sets of primers, used in two successive
runs of
polymerase chain reaction, the second set intended to amplify the target from
the first run
product.
[0040] As used herein, the term "oligonucleotide" refers to a short polymer
composed of
deoxyribonucleotides, ribonucleotides, or any combination thereof.
Oligonucleotides are
generally between about 10, 11, 12, 13, 14, 15, 20, 25, or 30 to about 150
nucleotides (nt) in
length, more preferably about 10, 11, 12, 13, 14, 15, 20, 25, or 30 to about
70 nt.
[0041] The term "specific" as used herein in reference to an
oligonucleotide primer means
that the nucleotide sequence of the primer has at least 12 bases of sequence
identity with a
portion of the nucleic acid to be amplified when the oligonucleotide and the
nucleic acid are
aligned. An oligonucleotide primer that is specific for a nucleic acid is one
that, under the
stringent hybridization or washing conditions, is capable of hybridizing to
the target of interest
and not substantially hybridizing to nucleic acids which are not of interest.
Higher levels of
sequence identity are preferred and include at least 75%, at least 80%, at
least 85%, at least
90%, at least 95% and more preferably at least 98% sequence identity.
- 10 -
CA 02980327 2017-09-19
WO 2016/154584 PCT/US2016/024319
[0042] As used herein, the term "subject" or "individual" refers to a
mammal, such as a
human, but can also be another animal such as a domestic animal (e.g., a dog,
cat, or the like), a
farm animal (e.g., a cow, a sheep, a pig, a horse, or the like) or a
laboratory animal (e.g., a
monkey, a rat, a mouse, a rabbit, a guinea pig, or the like).
[0043] The terms "complement," "complementary" or "complementarity" as used
herein
with reference to polynucleotides (i.e., a sequence of nucleotides such as an
oligonucleotide or a
genomic nucleic acid) related by the base-pairing rules. The complement of a
nucleic acid
sequence as used herein refers to an oligonucleotide which, when aligned with
the nucleic acid
sequence such that the 5' end of one sequence is paired with the 3' end of the
other, is in
"antiparallel association." For example, for the sequence 5'-A-G-T-3' is
complementary to the
sequence 3'-T-C-A-5'. Certain bases not commonly found in natural nucleic
acids may be
included in the nucleic acids of the present invention and include, for
example, inosine and 7-
deazaguanine. Complementarity need not be perfect; stable duplexes may contain
mismatched
base pairs or unmatched bases. Those skilled in the art of nucleic acid
technology can determine
duplex stability empirically considering a number of variables including, for
example, the
length of the oligonucleotide, base composition and sequence of the
oligonucleotide, ionic
strength and incidence of mismatched base pairs. Complementarity may be
"partial" in which
only some of the nucleic acids' bases are matched according to the base
pairing rules. Or, there
may be "complete," "total," or "full" complementarity between the nucleic
acids.
[0044] "Detecting" a mutation in a gene or protein may be accomplished by
performing an
appropriate assay. To detect a mutation in a gene or protein in a biological
sample, the
biological sample is assayed to determine the presence or absence of the
mutated gene or
mutated protein. The assay may include extracting nucleic acid (such as, for
example, total
genomic DNA and/or RNA) from the sample and analyzing the extracted nucleic
acid by
methods known in the art. An assay may involve isolating protein from the
biological sample
and analyzing the protein. However, an assay need not involve either
extraction of nucleic acid
or isolation of protein. That is, some assays may be employed that directly
analyze a biological
sample without extracting or isolating nucleic acid or protein.
[0045] As used herein, the term "subject" refers to a mammal, such as a
human, but can also
be another animal such as a domestic animal (e.g., a dog, cat, or the like), a
farm animal (e.g., a
- 11 -
CA 02980327 2017-09-19
WO 2016/154584 PCT/US2016/024319
cow, a sheep, a pig, a horse, or the like) or a laboratory animal (e.g., a
monkey, a rat, a mouse, a
rabbit, a guinea pig, or the like). The term "patient" refers to a "subject"
who possesses, or is
suspected to possess, a genetic polymorphism of interest.
[0046] Overview
[0047] Genomic sequence analysis using the Illumina MiSeq sequencing system
using the
supplied MiSeq Reporter software for the detection of BRCA1 and BRCA2 variants
is unable to
detect certain key mutations. Specifically, the MiSeq sequencing system has a
lower sensitivity
for certain types of variants, such as medium-sized insertions or deletions.
For example, as
described herein in the working examples, the MiSeq sequencing system was
unable to identify
two pathological BRCA1 variants having deletions of greater than 9 base pairs
(bp): the 40-bp
deletion c.1175 1214de140 and the 10-bp deletion c.3481 3491de110. A sequence
data analysis
pipeline (QSAP for Quest Sequence Analysis Pipeline) for processing raw
sequence data
generated from next generation sequence (NGS) platforms was developed for the
detection of
BRCA1 and BRCA2 variants and is described herein. The QSAP workflow as
described herein
can be used in conjunction with various NGS platforms for alignment and allele
assignment. In
some embodiments, the QSAP method is able to identify variants that are missed
by the MiSeq
Reporter software.
[0048] With respect to a genomic reference sequence, different fragments in
a sheared
genomic library tend to start and/or end at different locations than the start
and/or end locations
of other fragments. The QSAP workflow provided herein involves mitigation of
possible effects
of amplification bias by removing apparent PCR clones, thereby better
recovering the allele
balance present in the original sheared genomic sample. Therefore, the
bioinformatics analyses
are able to differentiate among reads from the same versus different library
clones. In addition,
the QSAP workflow involves local realignment limited to target regions of
interest, which
improves sensitivity of detection for insertions and deletions and a quicker,
more efficient
analysis.
[0049] In addition, the use of bait tile library exon capture followed by
NGS can avoid
potential causes of false-negative testing due to allele drop-out when
polymorphisms are
present in amplification or sequencing primer sequences. Bait tiles are
biotinylated RNA
molecules approximately 125-bp in length used to capture relevant fragments.
Since the bait
- 12 -
CA 02980327 2017-09-19
WO 2016/154584 PCT/US2016/024319
tiles are about 100 bases longer than typical PCR or sequencing primers and
RNA/DNA
hybrids are stronger than DNA/DNA hybrids, polymorphisms are less likely to
interfere with
the exon capture. A second advantage of bait tile capture versus PCR based
sequencing
methods is the avoidance of false positive results due to clonal bias in PCR
or library formation.
[0050] Target Genes and Variants
[0051] The systems and methods provided herein can be applied to the detection
of a variant
in any gene of interest. Exemplary variants include single nucleotide
polymorphisms, point
mutations, insertions, deletions, and translocations. In some exemplary
embodiments, the
system and methods provided herein are used for the detection of genomic
deletions of greater
than 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35,
40, 45, 50 or greater base
pairs.
[0052] In some exemplary embodiments, the gene of interest is a BRCA1 gene or
a BRCA2
gene. A BRCA/ or BR4CA2 target segment that is sequenced may represent all or
part of a
BRCA/ or BRACA2 genomic DNA or cDNA. In some embodiments, one or more BRCA/ or
BRACA2 exons or portions thereof are sequenced. In some embodiments, one or
more of the
BRCA/ or BR4CA2 introns or portions thereof are sequenced. In some
embodiments, from at
least one, two, five, 10 or 20 up to 25 or 27 exons are sequenced. In other
embodiments, all or a
portion of the BRCA/ or BRACA2 promoter region is also evaluated.
[0053] In some embodiments the target segments represent the entire coding and
noncoding
sequences of the BRCA/ or BR4CA2 gene. In one embodiment, the BRCA/ or BR4CA2
target
segments, when combined, represent the BRCA1 or BRACA2 coding region and all
introns, plus
from about 100, 500, 750, 900 or 1000 up to about 1200 nucleotides of the
BRCA1 or BRACA2
promoter immediately upstream (in the 5 prime direction) of the first exon
plus from about 50,
100, 150 or 200 up to about 200, 250, 300 or 400 nucleotides immediately
downstream (in the 3
prime direction) of the BRCA/ or BRACA2 gene. In some embodiments, the
adjacent, upstream
region comprises all or a portion of the BRCA1 or BRACA2 promoter sequence. In
another
embodiment, all exons and a portion of one or more introns of BRCA1 or BRACA2
are
represented.
[0054] In some embodiments the variant for detection is a pathogenic mutation
in BRCA1
gene or a BRCA2 gene. In some embodiments, the pathogenic mutation is selected
from a
- 13 -
CA 02980327 2017-09-19
WO 2016/154584
PCT/US2016/024319
mutation provided in Table 1. In some embodiments the variant for detection is
c.1175 1214de140 deletion or a c.3481 3491de110 deletion in the BRCA1 gene.
Table 1. BRCA1 and BRCA2 Variants in the 27 Coriell Cell Line Reference
Samples
dbSNP HGVS names
Sample NM 007300.3 NP 009231.2
BR
GM13711 c.3119G>A p.Ser1040Asn
GM13715 c.5326 5327insC p.Ser1776delinsSerProfs
GM14634 c.4065 4068delTCAA p.Asn1355 Gln1356delinsLysfs
GM14636 c.5621 5622insA p.Tyr1874delinsTerProfs
GM14637 c.4327C>T p.Arg1443Ter
GM14638 c.213-11T>G
GM14684 c.797 798delTT p.Va1266=fs
GM14090 c.66 67del AG p.Leu22 Glu23delinsLeuValfs
GM14092 c.5201T>C p.Va11734Ala
GM14093 c.1204delG p.G1u402Serfs
GM14094 c.1175 1214de140 p.Leu392 Ser405delinsGlnfs
GM14095 c.5200delG p .Val 1 734Terfs
GM14096 c.3481_3491delGAAGATACTAG p.G1u1161 Ser1164delinsPhefs
GM14097 c.181T>G p.Cys61Gly
GM13714 c.5382 5383insC p.Asn1795G1nfs
GM13713 c.3748G>T p.G1u1250Ter
GM13712 c.2155 2156insA p.Lys719delinsLysArgfs
GM13710 c.4327C>G p.Arg1443Gly
GM13709 c.2068delA p.Lys690=fs
GM13708 c.4752C>G p.Tyr1584Ter
GM13705 c.3756 3759delGTCT p.Leu1252 Ser1253delinsLeufs
BRCA2
GM14170 c.5946delT p.Ser1982Argfs
GM14622 c.6275_6276delTT p.Leu2092Profs
GM14623 c.125A>G p.Tyr42Cys
GM14624 c.5718 5719delCT p.Asn1906 Ser1907=fs
GM14626 c.9976A>T p.Lys3326Ter
GM14639 c.6198 6199delTT p.Va12066 Ser2067delinsValHisfs
- 14 -
CA 02980327 2017-09-19
WO 2016/154584 PCT/US2016/024319
All mutations were detected by NGS with the PGM system and the MiSeq system
(with QSAP
variant calling) software, as well as by Sanger sequencing.
[0055] Samples for Analysis and Sample Preparation
[0056] The methods provided herein can be applied to any nucleic acid obtained
from a
biological sample. The term "biological sample" as used herein refers to a
sample containing a
nucleic acid of interest. A biological sample may comprise a clinical sample
(i.e., obtained
directly from a patient) or isolated nucleic acids and may be cellular or
acellular fluids and/or
tissue (e.g., biopsy) samples. In some embodiments, a sample is obtained from
a tissue or bodily
fluid collected from a subject. Sample sources include, but are not limited
to, sputum (processed
or unprocessed), bronchial alveolar lavage (BAL), bronchial wash (BW), whole
blood or
isolated blood cells of any type (e.g., lymphocytes), bodily fluids,
cerebrospinal fluid (CSF),
urine, plasma, serum, or tissue (e.g., biopsy material). Methods of obtaining
test samples and
reference samples are well known to those of skill in the art and include, but
are not limited to,
aspirations, tissue sections, drawing of blood or other fluids, surgical or
needle biopsies,
collection of paraffin embedded tissue, collection of body fluids, collection
of stool, and the
like. In the present context the biological sample preferably is blood, serum
or plasma. The term
"patient sample" as used herein refers to a sample obtained from a human
seeking diagnosis
and/or treatment of a disease or determining the likelihood of developing a
disease.
[0057] Exemplary methods for the preparation of a genomic DNA sample include,
but are not
limited to DNA isolation, genomic DNA shearing, measuring DNA concentration,
DNA end
repair, adaptor ligation, amplification, and enrichment methods, e.g. bait
capture methods. An
exemplary process flow for the preparation of the DNA sample is provided in
Figure 1 and
further described in the examples provided herein.
[0058] In exemplary embodiments, genomic DNA is isolated from a patient sample
and
randomly sheared into genomic DNA fragments having an average size of about
250 base pairs.
In some embodiments, the isolated genomic DNA can be further purified and
concentrated. For
example, the isolated genomic DNA can be purified on a solid support such as
solid-phase
reversible immobilization (SPRI) beads.
[0059] In exemplary embodiments, nucleic acid adaptors are added to the 5' and
3' ends of
genomic DNA fragments. In some embodiments, at least one adapter contains a
unique index
- 15 -
CA 02980327 2017-09-19
WO 2016/154584 PCT/US2016/024319
sequence (also referred to as an index tag, a "barcode" or a multiplex
identifier (MID)) that is
used to identify individual DNA samples. Indexed nucleic acids from more than
one sample
source can be quantified individually and then pooled prior to sequencing. As
such, the use of
index sequences permits multiple samples (i.e., samples from more than one
sample source) to
be pooled per sequencing run and the sample source subsequently ascertained
based on the
index sequence.
[0060] In addition, the adaptors may comprise universal sequences useful for
priming for
amplification and/or sequencing reactions. In some embodiments, the genomic
DNA fragments
are amplified prior to sequencing. In some embodiments, the adapter sequences
are P5 and/or
P7 adapter sequences that are recommended for Illumina sequencers (MiSeq and
HiSeq). See,
e.g., Williams-Carrier et al., Plant J., 63(1):167-77 (2010). In some
embodiments, the adapter
sequences are P1 or A adapter sequences that are recommended for Life
Technologies
sequencers. Other adapter sequences are known in the art. Some manufacturers
recommend
specific adapter sequences for use with the particular sequencing technology
and machinery that
they offer.
[0061] The adaptors can be attached by ligation reaction or via amplification
using adapter-
ligated and/or indexed primers. When adapter-ligated and/or indexed primers
are employed to
amplify a target segment, the adapter sequence and/or index sequence gets
incorporated into the
amplicon (along with the target-specific primer sequence) during
amplification.
[0062] In exemplary embodiments, particular sequence targets are enriched.
Many methods
are available for sequence selection. In one example, suitable nucleic acid
probes are
immobilized on a solid support as a bait to capture polynucleotide fragments
having
complementary sequences. For example, selected target regions of the genome
can be enriched
by generating a pool of genomic DNA fragments by nucleic acid shearing and
sequence-specific
capture with nucleic acid probes (i.e. baits). The baits can be complementary
to one or more
exons, introns and/or splice junction sites located within the region or
regions of interest. In
some embodiments, the baits are RNA baits. In some embodiments, the baits are
tagged (e.g.
biotinylated) to facilitate purification of the genomic fragments (e.g.
purification with
streptavidin- coated beats to adsorb the biotinylated baits). In some
embodiments, the baits are
biotinylated RNA baits. In some embodiments, the baits are biotinylated RNA
baits
- 16 -
CA 02980327 2017-09-19
WO 2016/154584 PCT/US2016/024319
complimentary to one or more exons, introns and/or splice junction sites
located within the
BRCA/ and/or BRCA2 genes.
[0063] Prior to sequencing, additional sequences required for NGS sequencing,
for example
the Illumina MiSeCITM (Illumina, San Diego, CA) or Ion TorrentTm Personal Gene
Machine
(PGM) (Life Technologies, Grand Island, NY) sequencing platforms, can be added
to the 5' and
3' adaptors by amplification using primers specific for the adaptor sequences.
[0064] Control samples from cell lines or nucleic acid samples with known
deleterious
variants in the gene or genes of interest can be employed for comparison to a
test sample
containing a nucleic acid of unknown sequence.
[0065] NGS Sequencing Platforms
[0066] Generation of sequence data is typically performed using a high
throughput DNA
sequencing system, such as a next generation sequencing (NGS) system, which
employs
massively parallel sequencing of DNA templates. Exemplary NGS sequencing
platforms for the
generation of nucleic acid sequence data include, but are not limited to,
Illumina's sequencing
by synthesis technology (e.g., Illumina MiSeq or HiSeq System), Life
Technologies' Ion
Torrent semiconductor sequencing technology (e.g., Ion Torrent PGM or Proton
system), the
Roche (454 Life Sciences) GS series and Qiagen (Intelligent BioSystems) Gene
Reader
sequencing platforms.
[0067] Generally, two methods are used in preparing templates for NGS
reactions: amplified
templates originating from single DNA molecules, and single DNA molecule
templates. For
imaging systems which cannot detect single fluorescence events, amplification
of DNA
templates is required. The three most common amplification methods are
emulsion PCR
(emPCR), rolling circle and solid-phase amplification.
[0068] In clonal bridge amplification methods, which is used in Illumina HiSeq
and MiSeq
Systems, forward and reverse primers are covalently attached at high-density
to the slide in a
flow cell. The ratio of the primers to the template on the support defines the
surface density of
the amplified clusters. The flow cell is exposed to reagents for polymerase-
based extension, and
priming occurs as the free/distal end of a ligated fragment "bridges" to a
complementary oligo
on the surface. Repeated denaturation and extension results in localized
amplification of DNA
- 17 -
CA 02980327 2017-09-19
WO 2016/154584 PCT/US2016/024319
fragments in millions of separate locations across the flow cell surface.
Solid-phase
amplification produces about 12-15 million (MiSeq) spatially separated
template clusters (or
about 100-200 million for HiSeq), providing free ends to which a universal
sequencing primer
is then hybridized to initiate the sequencing reaction. Sequencing is then
generally carried out
using a reversible dye terminator method, which uses reversible terminator-
bound dNTPs in a
cyclic method that comprises nucleotide incorporation, fluorescence imaging
and cleavage. A
fluorescently-labeled terminator is imaged as each dNTP is added and then
cleaved to allow
incorporation of the next base. These nucleotides are chemically blocked such
that each
incorporation is a unique event. An imaging step follows each base
incorporation step, then the
blocked group is chemically removed to prepare each strand for the next
incorporation by DNA
polymerase. This series of steps continues for a specific number of cycles, as
determined by
user-defined instrument settings.
[0069] In emulsion PCR methods, a DNA library is first generated through
random
fragmentation of genomic DNA. Single-stranded DNA fragments (templates) are
attached to the
surface of beads with adaptors or linkers, and one bead is attached to a
single DNA fragment
from the DNA library. The surface of the beads contains oligonucleotide probes
with sequences
that are complementary to the adaptors binding the DNA fragments. The beads
are then
compartmentalized into water-oil emulsion droplets. In the aqueous water-oil
emulsion, each of
the droplets capturing one bead is a PCR microreactor that produces amplified
copies of the
single DNA template. These beads are then used to generate the sequence. The
beads used in
the amplification solution are covered with covalently bound oligonucleotides
that are antisense
to the P1 sequence of the library. Micro-chambers are created by the Ion
Torrent One Touch
Instrument 2 (0T2, Life Technologies, Grand Island, NY), which carries out
clonal
amplification. The strand of DNA that results from extension of the anti-sense
P1
oligonucleotide is then hybridized at its 3' end with a sequencing primer that
binds at the anti-
sense A oligonucleotide. DNA polymerase is added to the beads and then the
beads are
deposited into tiny pores on the surface of a computer chip-like surface. Each
of the four dNTPs
is then sequentially flowed in excess over the surface of the chip. The DNA
polymerase extends
the growing strand when the required nucleotide is made available. Whenever a
nucleotide is
added, a hydrogen molecule is released resulting in a pH change in the pore
containing the
sequencing bead. The magnitude of the pH change is approximately equal to the
number of
- 18 -
CA 02980327 2017-09-19
WO 2016/154584 PCT/US2016/024319
nucleotides incorporated and is detected and measured along with which of the
four nucleotides
that flowed through.
[0070] QSAP Methods of Processing data
[0071] Figure 2 illustrates a flow diagram in accordance with various
illustrative
implementations for the sequence data analysis (i.e., QSAP, Quest Sequence
Analysis Pipeline).
The process shown in Figure 2 can be implemented on a computing device. In one
implementation, the process is encoded on a computer-readable medium that
contains
instructions that, when executed by a computing device, cause the computing
device to perform
operations of process.
[0072] The raw nucleic acid sequencing data from a nucleic acid sequencer,
for example
from an NGS sequencing platform, which generates a plurality of nucleic acid
sequence data
from a plurality of nucleic acid fragment reads. Preferably, the data or data
sets are present in
one data format, more preferably in a unified data format, e.g. in the FASTQ
format, along with
their base quality either in Phred/Phrap or modified format. It is preferred
that the data format at
least covers the sequence read and its associated base quality. In some
embodiments, the
plurality of raw sequence data may be converted into a unified format.
[0073] This raw nucleic acid sequencing data is run through the QSAP method
provided
herein, which comprises an improved process for sequence alignment and variant
calling,
leading to improved detection of sequence variants. The QSAP method uses a
high performance
computing infrastructure, which a combination of open source and modified
sequencing tools.
The method includes the Burrows Wheeler Aligner (BWA) for alignment mapping to
a
reference sequence, for example, the hg19/GRCh37.1 reference genome, Queue
with the
Genome Analysis Tool Kit (GATK) for deduplication, a modified Smith-Waterman
local
realignment, and forced variant calling (e.g., modified GATK for variant
calling). In one
embodiment, soft clipping during alignment mapping is turned off For example,
the bwa tool
can be run with no soft clipping. A soft-clipped sequence is an unmatched
fragment in a
partially mapped read. In some embodiments, removing soft clipping eliminates
errors due to
incorrect mapping of reads that are soft clipped. Local realignment increases
the sensitivity of
mutation detection, including detection of large inserts and deletions. The
pipeline is designed
to maximize the accuracy of variant calls, reduce time of analysis and permit
ready access to
- 19 -
CA 02980327 2017-09-19
WO 2016/154584 PCT/US2016/024319
sample Binary alignment/Map format (BAM) and Variant Call Format (VCF) files.
Exemplary
embodiments for each step of QSAP method is provided herein below. The
"reference
sequence" as used herein may be any suitable preexisting sequence covering the
stretch, which
is identical or similar to the newly obtained sequence data or nucleic acid
fragment reads.
[0074] In exemplary methods, sample nucleotide sequence files, for example
FASTQ files,
are first copied from the nucleic acid sequencer, (e.g., MiSeq instrument)
into a user rundata
folder. The sequences are de-multiplexed using index reads on-instrument. The
raw FASTQ
files comprise at least 2 reads per sample, e.g., forward and reverse reads.
[0075] The sample FASTQ files are then filtered to remove reads flagged as
failing a vendor
quality filter. In some embodiments, the filter is a base quality, coverage,
complexity of the
surrounding region or length of mismatch filter. The filtering procedure can
be performed using
a sequence sorting utility, such as, for example, SAMtools (Sequence
Alignment/Map tools).
[0076] The adapter and Molecular Identifier (MID) tag sequences (i.e.
identifier sequences
ligated to the sample's sequence during the nucleic acid sample preparation
process) are then
trimmed from the sequence reads. In one implementation, this process is done
using a FASTQ
processing utility, such as fastq-mcf, which scans a sequence file for the
adapters and tag
sequences, and, based on a log-scaled threshold, determines a set of clipping
parameters and
performs clipping. This step produces a file containing the trimmed sample
FASTQ reads. The
sorted samples have a unique combined adaptor and MID sequence. Thus, trimming
is
performed according the identity of the adaptor and sample specific-MID
sequences to ensure
the both the adapter and MID sequences are removed during the trimming
process.
[0077] The trimmed reads are then mapped to a reference sequence (e.g., a
GRCh37.1 human
genome reference) suitable reference alignment algorithm, sorted and indexed.
This part of the
process can be performed using a Burrows-Wheeler Aligner (BWA) (e.g. version
0.7.5a-r405)
(e.g., using the command: bwa mem -M -t 2) and SAMtools. In some embodiments,
soft
clipping during alignment mapping is turned off. Alternative basic alignment
tools (e.g., bowtie)
can also be employed for the initial alignment. Read groups can then be added
to the BAM file
using a utility, such as Picard, which comprises Java-based command-line
utilities for
manipulating SAM and BAM format files. The output of this step is a raw BAM
file that
contains all reads for each sample mapped to the genome. While SAMtools
represents a
- 20 -
CA 02980327 2017-09-19
WO 2016/154584 PCT/US2016/024319
standard utility for the sorting and indexing of BAM files, other utilities
that can process BAM
files can be employed. Details and ways of implementing these alignment
algorithms are known
to the person skilled in the art, or can be derived from suitable literature
sources, e.g. from Bao
et al., Journal of Human Genetics, 28 Apr. 2011, p. 1-9, which is incorporated
herein by
reference in its entirety. The present invention further envisages the use of
optimized or further
developed versions of these algorithms, or of reference alignment algorithms
following a
different scheme or algorithmic logic including not yet available algorithms,
as long as the
principle purpose of an alignment to a reference sequence as described herein
is fulfilled.
[0078] The next step of the process involves pipelined realigner target
creation, local realign,
and flagging of duplicate reads. In some implementations, Queue can be used
for these steps. In
one exemplary implementation, the Queue pipeline is a modified Queue pipeline
based on the
DataProcessingPipeline.scala script included in the Queue v.2.3-9
distribution. In some
exemplary embodiments, modifications include one or more for the following:
the memory and
thread usage parameters are customized to fit the computing platform, the
modified Smith-
Waterman local realign option is used, the base quality score recalibration
step (BQSR) is
removed, and/or the Queue analysis and BAM output is limited to the regions of
interest (e.g.,
coding exons +/- about 50 bases) optionally padded by additional bases, e.g.
about 150 bases. In
some embodiments, removal of apparent duplicate fragments (i.e.,
deduplication) is performed
using picard's MarkDuplicates application, which can be pipelined using Queue.
The output of
these steps is a processed sequence BAM file that contains all reads for each
sample, realigned
to the region of interest and with duplicates removed.
[0079] In some embodiments, the base quality score recalibration (BQSR) is
removed to
improve compute time constraints. Such modification is useful in instances
where a relatively
small region of interest is sequenced, e.g., a few selected genes of interest.
When focusing on
smaller regions of interest, BQSR does not function as well because it relies
on having a broad
enough sampling of the genome that common variants (e.g. if the reference
sequence contains a
rare allele, most samples will have a variant at that position) do not
interfere with the
recalibration.
[0080] Local realignment is important for insertion and deletion sensitivity.
While the
modified Smith-Waterman alignment is a standard utility for alignments, it is
computational
-21 -
CA 02980327 2017-09-19
WO 2016/154584 PCT/US2016/024319
intensive. In the methods provided herein, a modified Smith-Waterman local
realign is used
which limits the realignment to regions of interest, e.g., a few selected
genes of interest (e.g.,
BRCA1 and BRCA2 genes). This modification decreases the computational duration
of the
realigner target creation and local realign steps. This also leads to quicker
and more efficient
system as run times can be reduced.
[0081] Deduplication is important in order to minimize the effect of
amplification bias. It
functions to remove apparent PCR duplicates by flagging reads that have the
same start and end
points when aligned against the reference sequence. Because shearing is
random, it is unlikely
that a fragment would share both a start point and an end point by chance, so
those fragments
are removed from the downstream analysis (only the highest quality fragment of
the apparently
clonal group is retained). After deduplication, the allele balance of
heterozygous variants tends
to be close to the expected 50%, which is important for sensitivity (e.g., if
it drops too low due
to amplification bias, the variant might be missed) and zygosity detection
(e.g. if it is too high,
then it could be mistaken for homozygous). The upstream bench process
described herein for
the preparation of the samples by bait capture and deduplication in the
bioinformatics process
facilitates a desirable allele balance.
[0082] Variants are then called at every position in the regions of interest
(coding exons +/-
SO bases). In one implementation, the UnifiedGenotyper in GATK v 2.3-9 can be
used. In one
particular embodiment GATK is employed using discovery mode, emitting all
sites, calling
indels and point mutations, with a maximum alternate alleles setting of two,
and an indel gap
opening penalty of 30. Calling all variants at every position ensures that no
variant calls are
suppressed. Ensuring that no variant calls are suppressed is important to the
present method. For
example, if a variant call is suppressed, deletions can be missed, leading to
less accurate results.
After forcing a variant call at every position, the positions not having
variants are filtered out
and the remaining variants proceed to downstream processing.
[0083] Variant calling in GATK can be performed in discovery mode or in
genotyping mode,
where a list of variants are supplied to call presence or absence. In some
embodiments, both
types of variant calling can be performed and the results combined, in order
to maximize
sensitivity. Such methods can address issues observed with different
amplification protocols in
the preparation of the samples (e.g. where PCR duplicates could not be
removed).
- 22 -
CA 02980327 2017-09-19
WO 2016/154584 PCT/US2016/024319
[0084] In specific embodiments of the present invention, a filter or threshold
may accordingly
be implemented to distinguish between sequence data showing an acceptable base
quality and a
non-acceptable base quality. The term "acceptable base quality" as used herein
refers to a phred-
like quality score of about 20 and higher. A phred-like quality score is a Q
score which is -10
logio(e) where e is the estimated probability of the base call being wrong.
The method is
typically used to measure the accuracy of sequencing data. Higher quality
scores indicate a
smaller probability that a base is called incorrectly. A quality score of 20
thus represents an
error rate of 1 in 100, with a corresponding call accuracy of 99%. In further
specific
embodiments of the present invention a filter or threshold may be implemented
to distinguish
between sequence data showing an acceptable coverage and a non-acceptable
coverage. The
term "acceptable coverage" as used herein refers to a coverage of about 20x
and above.
Accordingly, the number of reads covering a base in an alignment is about 20,
or more.
[0085] In further specific embodiments of the present invention, a filter or
threshold may be
implemented to distinguish between sequence data showing an acceptable high
complexity of
the surrounding region and a medium to low complexity of the surrounding
region. The term
"high complexity of the surrounding region" as used herein refers to the
presence of repeated
sequences stretches, e.g. the presence of repeated dimers, trimers, the
presence of transposon
remnants or repeated sequences derived from transposons etc.
[0086] In yet another specific embodiment of the present invention a filter or
threshold may
be implemented to distinguish between sequence data showing an acceptable
length of
mismatch and non-acceptable length of mismatch. The term "acceptable length of
mismatch" as
used herein refers to gaps that does not allow complete matching of a read to
the reference
sequence. A corresponding matching may be a continuous and non-continuous
matching of
about 70% and more.
[0087] Binary alignment/Map format
[0088] Figure 6 is a block diagram of a computer system in accordance with an
illustrative
implementation. The computer system can be used for the sequence data analysis
described
above, including performance of one or more or all steps of the QSAP pipeline.
The exemplary
computing system 600 includes a bus 605 or other communication component for
communicating information and a processor 610 or processing circuit coupled to
the bus 605 for
- 23 -
CA 02980327 2017-09-19
WO 2016/154584 PCT/US2016/024319
processing information. The computing system 600 can also include one or more
processors 610
or processing circuits coupled to the bus for processing information. The
computing system 600
also includes main memory 615, such as a random access memory (RAM) or other
dynamic
storage device, coupled to the bus 605 for storing information, and
instructions to be executed
by the processor 610. Main memory 615 can also be used for storing position
information,
temporary variables, or other intermediate information during execution of
instructions by the
processor 610. The computing system 600 may further include a read only memory
(ROM) 620
or other static storage device coupled to the bus 605 for storing static
information and
instructions for the processor 610. A storage device 625, such as a solid
state device, magnetic
disk or optical disk, is coupled to the bus 605 for persistently storing
information and
instructions.
[0089] The computing system 600 may be coupled via the bus 605 to a display
635, such as
a liquid crystal display, or active matrix display, for displaying information
to a user. An input
device 630, such as a keyboard including alphanumeric and other keys, may be
coupled to the
bus 605 for communicating information and command selections to the processor
610. In
another implementation, the input device 630 has a touch screen display 635.
The input device
630 can include a cursor control, such as a mouse, a trackball, or cursor
direction keys, for
communicating direction information and command selections to the processor
610 and for
controlling cursor movement on the display 635.
[0090] According to various implementations, the processes described herein
can be
implemented by the computing system 600 in response to the processor 610
executing an
arrangement of instructions contained in main memory 615. Such instructions
can be read into
main memory 615 from another computer-readable medium, such as the storage
device 625.
Execution of the arrangement of instructions contained in main memory 615
causes the
computing system 600 to perform the illustrative processes described herein.
One or more
processors in a multi-processing arrangement may also be employed to execute
the instructions
contained in main memory 615. In alternative implementations, hard-wired
circuitry may be
used in place of or in combination with software instructions to effect
illustrative
implementations. Thus, implementations are not limited to any specific
combination of
hardware circuitry and software.
- 24 -
CA 02980327 2017-09-19
WO 2016/154584 PCT/US2016/024319
[0091] Although an example computing system has been described in Figure 6,
implementations described in this specification can be implemented in other
types of digital
electronic circuitry, or in computer software, firmware, or hardware,
including the structures
disclosed in this specification and their structural equivalents, or in
combinations of one or more
of them.
[0092] Implementations described in this specification can be implemented
in digital
electronic circuitry, or in computer software, firmware, or hardware,
including the structures
disclosed in this specification and their structural equivalents, or in
combinations of one or more
of them. The implementations described in this specification can be
implemented as one or
more computer programs, i.e., one or more modules of computer program
instructions, encoded
on one or more computer storage media for execution by, or to control the
operation of, data
processing apparatus. Alternatively or in addition, the program instructions
can be encoded on
an artificially-generated propagated signal, e.g., a machine-generated
electrical, optical, or
electromagnetic signal that is generated to encode information for
transmission to suitable
receiver apparatus for execution by a data processing apparatus. A computer
storage medium
can be, or be included in, a computer-readable storage device, a computer-
readable storage
substrate, a random or serial access memory array or device, or a combination
of one or more of
them. Moreover, while a computer storage medium is not a propagated signal, a
computer
storage medium can be a source or destination of computer program instructions
encoded in an
artificially-generated propagated signal. The computer storage medium can also
be, or be
included in, one or more separate components or media (e.g., multiple CDs,
disks, or other
storage devices). Accordingly, the computer storage medium is both tangible
and non-
transitory.
[0093] The operations described in this specification can be performed by a
data processing
apparatus on data stored on one or more computer-readable storage devices or
received from
other sources. The term "data processing apparatus" or "computing device"
encompasses all
kinds of apparatus, devices, and machines for processing data, including by
way of example a
programmable processor, a computer, a system on a chip, or multiple ones, or
combinations of
the foregoing. The apparatus can include special purpose logic circuitry,
e.g., an FPGA (field
programmable gate array) or an ASIC (application-specific integrated circuit).
The apparatus
- 25 -
CA 02980327 2017-09-19
WO 2016/154584 PCT/US2016/024319
can also include, in addition to hardware, code that creates an execution
environment for the
computer program in question, e.g., code that constitutes processor firmware,
a protocol stack, a
database management system, an operating system, a cross-platform runtime
environment, a
virtual machine, or a combination of one or more of them. The apparatus and
execution
environment can realize various different computing model infrastructures,
such as web
services, distributed computing and grid computing infrastructures.
[0094] A computer program (also known as a program, software, software
application,
script, or code) can be written in any form of programming language, including
compiled or
interpreted languages, declarative or procedural languages, and it can be
deployed in any form,
including as a stand-alone program or as a module, component, subroutine,
object, or other unit
suitable for use in a computing environment. A computer program may, but need
not,
correspond to a file in a file system. A program can be stored in a portion of
a file that holds
other programs or data (e.g., one or more scripts stored in a markup language
document), in a
single file dedicated to the program in question, or in multiple coordinated
files (e.g., files that
store one or more modules, sub-programs, or portions of code). A computer
program can be
deployed to be executed on one computer or on multiple computers that are
located at one site
or distributed across multiple sites and interconnected by a communication
network.
[0095] Processors suitable for the execution of a computer program include,
by way of
example, both general and special purpose microprocessors, and any one or more
processors of
any kind of digital computer. Generally, a processor will receive instructions
and data from a
read-only memory or a random access memory or both. The essential elements of
a computer
are a processor for performing actions in accordance with instructions and one
or more memory
devices for storing instructions and data. Generally, a computer will also
include, or be
operatively coupled to receive data from or transfer data to, or both, one or
more mass storage
devices for storing data, e.g., magnetic, magneto-optical disks, or optical
disks. However, a
computer need not have such devices. Moreover, a computer can be embedded in
another
device, e.g., a mobile telephone, a personal digital assistant (PDA), a mobile
audio or video
player, a game console, a Global Positioning System (GPS) receiver, or a
portable storage
device (e.g., a universal serial bus (USB) flash drive), to name just a few.
Devices suitable for
storing computer program instructions and data include all forms of non-
volatile memory,
- 26 -
CA 02980327 2017-09-19
WO 2016/154584 PCT/US2016/024319
media and memory devices, including by way of example semiconductor memory
devices, e.g.,
EPROM, EEPROM, and flash memory devices; magnetic disks, e.g., internal hard
disks or
removable disks; magneto-optical disks; and CD-ROM and DVD-ROM disks. The
processor
and the memory can be supplemented by, or incorporated in, special purpose
logic circuitry.
[0096] Data reporting/Output
[0097] Downstream of variant calling, a metrics report generator, e.g., QC
Metric (e.g.
number of reads, mean coverage, minimum coverage), can be used to calculate
regional
minimum coverage depths per sample (counting reads having a minimum of Q30 at
each
position in the region of interest), followed by result parsing and cataloging
in a purpose-built
database, where samples having minimum coverage below 20 reads (after removing
duplicate
reads) were flagged for repeat.
[0098] In some embodiments of the present invention, the sequence analysis
pipeline as
described herein above may be associated or connected to a diagnostic decision
support system.
A "diagnostic decision support system" as used herein refers to system
comprising an input for
providing a subject's sequence data and, in specific embodiments, optionally
its functional
readout, for example gene or non-coding RNA expression, or protein levels. In
addition, the
system comprises a program element or computer program or a software for
assembly of
nucleic acid sequence data comprising nucleic acid fragment reads into
contiguous nucleotide
sequence segments, which when being executed by a processor is adapted to
carry out the steps
of the method as defined herein above, and an output for outputting a
subject's contiguous
nucleotide sequence segment(s) variation, and a medium for storing the
outputted information.
Preferably, the outputted information is able to indicate the presence or
absence of genomic
modifications, more preferably the affliction of a subject by a disease or a
predisposition for a
disease.
[0099] An automated preliminary assessment can be performed on the variant
call file data
and retuned as an annotated file. The initial automated assessment can include
variant molecular
classification (e.g. synonymous, missense, nonsense, frameshift),
comprehensive clinical
evidence (largely curated by scientists from peer- reviewed literature) and
evidence-based
clinical decision support that assists the initial classification of the
observed variants. The
preliminary automated assessment improves the turnaround time and maximizes
the information
- 27 -
CA 02980327 2017-09-19
WO 2016/154584 PCT/US2016/024319
used for the final clinical assessment of variants. The assessment software
can be configured
using pre-defined scoring and classification rules, including American College
of Medical
Genetics recommended guidelines and/or a compilation of evidence including the
most recent
literature. The assessment software can provide reviewers with direct access
to the relevant
literature for variants as well as providing transparency to how the automated
assessments were
derived to facilitate review of primary data. Final classification can also be
perform using
manual review through a web interface, additional locus-specific databases and
confirmatory
queries.
[00100] Sequencing data or assessment analyses can be reported to a certified
laboratory, to a
physician, or directly to the patient. Customized visualization can used to
manually review the
results for nomination to the clinical report. In yet another embodiment of
the present invention,
the diagnostic decision support system may be an electronic picture/data
archiving and
communication system.
[00101] The disease or disorder which may be detected or diagnosed or
prognosticated
according to the present invention may be any detectable disease known to the
person skilled in
the art. In a preferred embodiment, said disease may be a genetic disease or
disorder, in
particular a disorder, which can be detected on the basis of genomic sequence
data. Such
disorders include, but are not limited to, the disorders mentioned, for
example, in suitable
scientific literature, clinical or medical publications, qualified textbooks,
public information
repositories, internet resources or databases, in particular one or more of
those mentioned in
http://en.wikipedia.org/wiki/List of_genetic disorders.
[00102] In a particularly preferred embodiment of the present invention said
disease is a
cancerous disease, e.g. any cancerous disease or tumor known to the person
skilled in the art. In
particular embodiments, the disease is breast cancer, ovarian cancer, or
prostate cancer.
[00103] In a specific embodiment, said diagnostic decision support system may
be a molecular
oncology decision making workstation. The decision making workstation may
preferably be
used for deciding on the initiation and/or continuation of a cancer therapy
for a subject. Further
envisaged are similar decision making workstation for different disease types,
e.g. for any of the
diseases as mentioned herein above.
- 28 -
CA 02980327 2017-09-19
WO 2016/154584 PCT/US2016/024319
EXAMPLES
[00104] Example 1
[00105] This disclosure describes the development and validation of a rapid,
high-throughput
sequencing assay for the detection of BRCA1 and BRCA2 variants suitable for
the clinical
laboratory. Results from the initial 1006 clinical samples tested in duplicate
with the
MiSeq/QSAP combination showed no discrepant variant calls. In one
implementation, an NGS-
based assay using bait tile exon capture for detection of BRCA1/2 variants in
a reference
laboratory. During testing, two different NGS platforms were employed: the
Illumina MiSeq
System and the Life Technologies Ion Torrent Personal Genome Machine. As
explained below,
results from the first 521 clinical samples were obtained using both NGS
platforms, and an
additional 1006 results were obtained using duplicate MiSeq runs.
[00106] Figure 1 illustrates the general overview of the NGS assay for
detection of BRCA1
and BRCA2 variants. The description below describes one implementation of the
invention.
[00107] DNA Samples
[00108] DNA samples from cell lines with known deleterious variants in BRCA1
(n=21; Table
1) or BRCA2 (n=6; Table 1) were purchased from the Coriell Mutant Cell
Repository (Camden,
NJ). Theses reference samples contained both pathogenic and nonpathogenic
variants. In one
implementation, blood samples from 67 unaffected individuals previously
untested for BRCA
mutations were obtained. Sanger sequencing was performed to determine the
presence of
BRCA1 or BRCA2 sequence variations. In this implementation, 352 benign
variants were
identified in the volunteer population and were used in the technical
validation.
[00109] DNA Preparation
[00110] Genomic DNA from peripheral blood cells was isolated in 96-well
microtiter plates
using a Roche MagnapureTM system from Roche Molecular Systems (Indianapolis,
IN) per the
manufacturer's instructions. Genomic DNA was randomly sheared to an average
size of 250
base pairs using adaptive focused acoustics technology (E220 Focused Ultra-
Sonicator, Covaris
Inc., Woburn, MA) according to the manufacturer's instructions.
[00111] Concentration via SPRI Beads and PEG/Sodium Chloride Mix
- 29 -
CA 02980327 2017-09-19
WO 2016/154584 PCT/US2016/024319
[00112] After shearing, the DNA was concentrated 2-fold and DNA molecules with
inadequate
sizes were removed. This was accomplished with SPRI (solid-phase reversible
immobilization)
beads (AMPure Beads, Agencourt, Beverley, MA). The beads were suspended in a
solution of
polyethylene glycol (PEG), EDTA.
[00113] DNA End Repair
[00114] The ends of the DNA molecules were repaired prior to adaptor ligation.
This was
accomplished using a DNA polymerase that has both 5' to 3' polymerase activity
and 3' to 5'
exonuclease activity, thereby filling in 5' overhangs and removing 3'
overhangs to generate
blunt ends. In addition, the 5' end of the DNA fragments were also
phosphorylated in this
process.
[00115] Adaptor Ligation and Nick Repair
[00116] Each 5' adaptor contains a unique molecular identification (MID)
sequence (barcode)
that is used to identify individual DNA samples. In addition, it contains a
portion of the P5
sequence. The 3' adaptor is universal to all specimens and contains a portion
of the P7 MiSeq
sequence. Neither adaptor is 5' phosphorylated. A short complimentary
oligonucleotide for each
of the adaptors can also be included in the ligation reaction to ensure that
the adaptors are only
ligated to the DNA fragments and not to themselves. During ligation the molar
ratios of the two
adaptors are equal to each other but are in excess in comparison to the
fragmented DNA.
Following this procedure, approximately half of all ligation products are the
preferred species,
namely: 5'-(P5)- MID-BRCA GeneDNA-universal (P7)-3'. The samples were cleaned
using
SPRI beads as described above, and the nicks at the ligation site were
repaired by a DNA
polymerase. The polymerase adds nucleotides at the nick site creating a primer
binding site for
PCR amplification.
[00117] Pre-hybridization Amplification
[00118] In order to increase the ratio of adapted DNA fragments, non-allele
specific PCR was
performed. The primers used were complementary to the 5' and the 3' adaptor
sequences.
[00119] Target Enrichment Through Exon Capture
[00120] All bar coded patient DNA fragments were pooled to create a "library,"
and were
added to a hybridization reaction mixture and incubated for 12 hours at 65 C.
This mixture
- 30 -
CA 02980327 2017-09-19
WO 2016/154584 PCT/US2016/024319
contained the biotinylated RNA baits. The baits were complimentary to BRCA1
and BRCA2
genes (exonic regions and splice junction sites, and a selected intronic
region) to allow
hybridization to the appropriate patient DNA fragments. After the
hybridization, the library was
combined with streptavidin coated beats to adsorb the biotinylated RNA baits.
The library-RNA
bait hybrids were washed at 70 C to remove the non-BRCA DNA.
[00121] Second Nonspecific Amplification
[00122] Additional sequences required for either the Illumina MiSeqTM
(Illumina, San Diego,
CA) or Ion TorrentTm Personal Gene Machine (PGM) (Life Technologies, Grand
Island, NY)
sequencing platforms were added to the 5' and 3' adaptors using fusion
primers. The DNA
library was divided into two halves. One half was amplified with fusion
primers (P5 and P7
sequences) that have a portion complementary to the 5' and 3' adaptors and add
additional
sequences for MiSeq sequencing and the other half was amplified with a set of
primers (P1 and
A sequences) that add additional sequences for PGM sequencing.
[00123] Quantification of DNA Concentration by Qubit
[00124] The high sensitivity Qubit kit (Life Technologies), which uses an
intercalating dye
based method, was used to quantify DNA.
[00125] NGS Sequencing
[00126] The prepared library was diluted so that amplification generated well-
separated
clusters of identical products from a single DNA molecule (i.e. clonal
amplification). The
MiSeq and PGM NGS protocols were performed according to the manufacturer's
protocols.
[00127] MiSeq
[00128] The single-stranded library was loaded into well 21 of the MiSeq
sequencing cartridge.
The instrument flushed the library through the flow cell where it hybridized
to the antisense P5
and P7 oligonucleotides that are complimentary to the adaptors on the library.
The library was
diluted so that amplification generated well-separated clusters of identical
products from a
single DNA molecule (clonal amplification). This was accomplished by
isothermal bridge
amplification. Fluorophore-labeled nucleotide triphosphates were applied to
the flow cell and
then excited by a laser. The emission spectra was recorded by the MiSeq, and
then the
- 31 -
CA 02980327 2017-09-19
WO 2016/154584 PCT/US2016/024319
nucleotide blocker, which inhibited further synthesis, was cleaved, allowing
for addition of the
next nucleotide triphosphate. In this manner, fragments were sequenced.
[00129] Ion Torrentrm PGM
[00130] The PGM uses emulsion PCR, the amplification inside of tiny water
droplets floating
in oil. Emulsion PCR is performed to get many copies of a single DNA molecule
onto a single
sequencing "bead" (i.e. clonal amplification). These beads are then used to
generate the
sequence. The beads used in the amplification solution are covered with
covalently bound
oligonucleotides that are antisense to the P1 sequence of the library. Micro-
chambers are
created by the Ion Torrent One Touch Instrument 2 (0T2, Life Technologies,
Grand Island,
NY), which carries out clonal amplification.
[00131] The strand of DNA that results from extension of the anti-sense P1
oligonucleotide is
then hybridized at its 3' end with a sequencing primer that binds at the anti-
sense A
oligonucleotide. DNA polymerase is added to the beads and then the beads are
deposited into
tiny pores on the surface of a computer chip-like surface. Each of the four
dNTPs is then
sequentially flowed in excess over the surface of the chip. The DNA polymerase
extends the
growing strand when the required nucleotide is made available. Whenever a
nucleotide is added,
a hydrogen molecule is released resulting in a pH change in the pore
containing the sequencing
bead. The magnitude of the pH change is approximately equal to the number of
nucleotides
incorporated and is detected and measured along with which of the four
nucleotides that flowed
through.
[00132] Bioinformatics Processing
[00133] Following the sequencing reaction, sequence alignment and allele
assignment was
performed. Initially, for the MiSeq the MiSeq ReporterTM software supplied
with the instrument
was used. This process, however, did not consistently identify deletions
larger than 9 bp. To
identify deletions larger than 9 bp, the following workflow, called QSAP, was
used. QSAP is a
bioinformatics pipeline. The QSAP is the specialized portion of the overall
workflow that
integrates open source, in-house developed and licensed modules for sequence
analysis. This
analysis pipeline, using a high performance computing infrastructure, includes
the Burrows
Wheeler Aligner (BWA) for mapping to the hg19/GRCh37.1 reference genome and
Queue with
the Genome Analysis Tool Kit (GATK) for deduplication, modified Smith-Waterman
local
- 32 -
CA 02980327 2017-09-19
WO 2016/154584 PCT/US2016/024319
realignment, and variant calling. The pipeline is designed to maximize the
accuracy of variant
calls, reduce time of analysis and permit ready access to sample Binary
alignment/Map format
(BAM) and Variant Call Format (VCF) files.
[00134] Specifically, following copying sample FASTQ nucleotide sequence files
from the
MiSeq instrument (demultiplexed using index reads on-instrument), the sample
FASTQ files
were filtered to remove reads flagged as failing a vendor quality filter. This
procedure can be
performed using a sequence sorting utility, such as, for example, SAMtools
(Sequence
Alignment/Map tools). The adapter and Molecular Identifier (MID) tag sequences
(i.e. identifier
sequences ligated to the sample's sequence during the nucleic acid sample
preparation process)
are trimmed. In one implementation, this process is done using a FASTQ
processing utility,
such as fastq-mcf, which scans a sequence file for adapters, and, based on a
log-scaled
threshold, determines a set of clipping parameters and performs clipping.
[00135] Following trimming, the reads were mapped to genomic reference, sorted
and indexed.
This can be done using a Burrows-Wheeler Aligner (e.g. version 0.7.5a-r405)
(e.g. using the
command: bwa mem -M -t 2) and SAMtools. Read groups can then added. The read
groups can
be added using Picard, which comprises Java-based command-line utilities for
manipulating
SAM files. The next steps of the process involved pipeline realigner target
creation, local
realign, and flagging of duplicate reads. In some implementations, Queue can
be used for these
steps. In one implementation, the Queue pipeline was based on the
DataProcessingPipeline.scala script included in the Queue v.2.3-9
distribution. The following
modifications were made in this implementation: customized the memory and
thread usage
parameters to fit the computing platform, used the modified Smith-Waterman
local realign
option, removed the base quality score recalibration step, and limited the
Queue analysis and
BAM output to the regions of interest (coding exons +/- 50 bases) padded by an
additional 150
bases. Variants were then called at every position in the regions of interest
(coding exons +/- 50
bases). In one implementation, the UnifiedGenotyper in GATK v 2.3-9 was used,
using
discovery mode, emitting all sites, calling indels and point mutations, with a
maximum alternate
alleles setting of two, and an indel gap opening penalty of 30.
[00136] For the PGM data, bioinformatics analyses were performed using the
Torrent SuiteTM
software supplied with the instrument.
- 33 -
CA 02980327 2017-09-19
WO 2016/154584 PCT/US2016/024319
[00137] Downstream of variant calling, a metrics report generator, e.g., QC
Metric (e.g.
number of reads, mean coverage, minimum coverage), can be used to calculate
regional
minimum coverage depths per sample (counting reads having a minimum of Q30 at
each
position in the region of interest), followed by result parsing and cataloging
in a purpose-built
database, where samples having minimum coverage below 20 reads (after removing
duplicate
reads) were flagged for repeat.
[00138] In some embodiments, the BRCA1/2 advanced sequencing bioinformatics
modular
workflow manages the sequence information from Illumina MiSeq FASTQ files to
final
reporting to a certified laboratory, e.g. CLIA (Clinical Laboratory
Improvement Amendments)
or CAP (College of American Pathologist) certified laboratory. In some
embodiments, the
workflow uses customized visualization to manually review the results for
nomination to the
clinical report.
[00139] In some embodiments, the de-identified VCF files are subjected to
automated
preliminary assessment, and an annotated file is generated. The initial
automated assessment
leverages variant molecular classification (e.g. synonymous, missense,
nonsense, frameshift),
comprehensive clinical evidence (largely curated by scientists from peer-
reviewed literature)
and provides evidence-based clinical decision support that assists the initial
classification of the
observed variants. The preliminary automated assessment improves the
turnaround time and
maximizes the information used for the final clinical assessment of variants.
The automated
assessment has two additional fundamental features. First, the assessment was
configured using
Quest Diagnostics pre-defined scoring and classification rules with American
College of
Medical Genetics recommended guidelines being the central advisement combined
with a
compilation of evidence including the most recent literature. Second, the
software provides
reviewers with direct access to the relevant literature for variants as well
as providing
transparency to how the automated assessments were derived to facilitate
review of primary
data. Subsequent manual review through Ingenuity's VCS web interface,
additional locus-
specific databases and confirmatory queries were carried out to complete the
final classification.
For the PGM data, bioinformatics analyses were performed using the Torrent
SuiteTM software
supplied with the instrument.
[00140] Variant assessment
- 34 -
CA 02980327 2017-09-19
WO 2016/154584 PCT/US2016/024319
[00141] Variant assessment is performed manually by a team of variant
scientists (VS)
according to the guidelines of the American College of Medical Genetics. VCF
files are
analyzed by the software program Alamut that provides genomic coordinates and
SIFT in vitro
functional analysis. The VS rechecks the quality metrics of the individual run
and, if the run
passes QC, proceeds to the assessment. At this point the deletion/duplication
results from the
MLPA reactions are also reviewed.
[00142] The VS then reviews the called variants to ensure concordance with the
IGV data. If
variant identification is accurate, the variants are loaded from Alamut HT
into a proprietary
database called QuestIQ. The following fields are automatically filled by the
Alamut HT
software interface: Gene Variant, Variant ID, Ref Seq, DNA level, Mutation
type, Code
Interpretation, PUC, Gene Code, Exon, Nucleotide, Change, Codon, Amino Acid,
dbSNP rs#,
dbSNP link, SIFT, Species conservation, Link to VUS analysis text, link to
Splicing Report, and
MolGen accession numbers.
[00143] The VS then searches for further information using gene specific
databases, e.g.,
UMD, BIC, LOVD, IARC, ClinVar, ARUP, kConFab, HGMD, InSIGHT. This is followed
by
assessing the variant frequency using ESP and dbSNP. If applicable, post
translation predictive
databases are used such as NetPhosk, NetPhos, ScanSite: S, T, Y
phosphorylation predictions,
Yin o Yang: 0-linked GlcNac prediction. Splicing predictions are made using
linked software
in Alamut HC, using the RefSeq database. The functional predictive programs
SIFT and
PolyPhen2 are then used.
[00144] Subsequently, a manual literature search is performed to determine if
there is further
supporting data on the particular variant using a Google search through
Alamut, PubMed,
ScienceDirect, and BioMed Central. All relevant results are entered into the
IQDB database.
[00145] The final variant classification is made according to the ACMG
guidelines, and the
result entered into the IQDB database. Classifications are scored as Benign,
Likely
Benign,VUS, Likely Pathogenic, Pathogenic. This result is then passed to a
director for
secondary review and report writing.
[00146] Results
[00147] Assay Development
- 35 -
CA 02980327 2017-09-19
WO 2016/154584 PCT/US2016/024319
[00148] During assay development, the MiSeq sequencing system using the
supplied MiSeq
Reporter software was unable to identify 2 of the pathological BRCA1 variants
in tested Coriell
samples. Both variants were deletions of >9 bp: the 40-bp deletion c.1175
1214de140 and the
10-bp deletion c.3481 3491de110. These were the only deletions of >9 bp in
these samples. The
QSAP workflow described above, however, can be used for alignment and allele
assignment
(QSAP) as described above. Figure 3 shows the alignment representation for the
sample
containing a 40-bp deletion. This deleterious mutation was identified by the
PGM/Torrent Suite
software but not the MiSeq/MiSeq Reporter software. However, the deletion was
clearly
identified when using MiSeq with QSAP software (Figure 3). Similar findings
were seen for the
10-bp deletion, with MiSeq/MiSeq reporter consistently missing the deletion
and the
PGM/Torrent Suite and MiSeq/QSAP always identifying the deletion (data not
shown). The
MiSeq/QSAP and the PGM/Torrent Suite combinations both showed 100% sensitivity
for the
BRCA1 and BRCA2 variants in the validation set. Technical validation using
both platforms
was performed.
[00149] Since NGS sequencing errors can result from PCR or clonal
amplification errors, QC
metric was developed to overcome these potential problems, taking advantage of
the fact that
random shearing leads to library clones that have different starting and
ending positions.
Therefore the bioinformatics analyses were able to differentiate among reads
from the same
versus different library clones. This enabled us to develop a minimum QC
metric, whereby each
targeted base must have high quality sequence from a minimum of 20 unique
clones. Typically
however, an "average depth of read" of 335 unique reads was achieved.
[00150] Technical Validation: Intra-assay Precision
[00151] Intra-assay precision was established by analyzing the DNA extracted
from three
blood samples, in five replicates on each platform. Each sample had at least
one BRCA1 or
BRCA2 variant. All variants identified in each sample were 100% concordant
within the five
replicates when detected on the MiSeq/QSAP combination. However, the
PGM/Torrent Suite
platform exhibited a low level of random sequencing errors. Overall intra-
assay concordance on
the PGM instrument was only 96.2%. In one sample, a single base insertion was
detected in the
fifth replicate that was not detected in the other replicates. In addition, a
benign variant was not
identified in the fourth replicate. In another sample, the fifth replicate
contained 4 SNPs that
- 36 -
CA 02980327 2017-09-19
WO 2016/154584 PCT/US2016/024319
were not present in any of the other replicates, and one SNP was called in
replicate 3 that was
not called elsewhere.
[00152] In comparing the MiSeq/QSAP allele calls to the PGM/Torrent Suite
calls, there were
several discordances. One sample showed discordance at 2 SNP sites between the
2 platforms:
PGM/Torrent Suite called an A insertion at position 32906554 on chromosome 13
in one of the
replicates that was not identified in the remainder of the PGM/Torrent Suite
replicates or on the
MiSeq/QSAP platform. The PGM/Torrent Suite also did not detect rs1799949 at
position
41245466 on chromosome 17 in one replicate. As a result, intra-specimen
concordance was
88% between the 2 platforms for this specimen. The second sample was
concordant on all
variant calls from both platforms, resulting in a concordance of 100% between
platforms. The
third sample was discordant at 5 of 11 SNPs due to sequencing errors on
PGM/Torrent Suite (1
of 5 replicates for each SNP), for a concordance rate of only 64%.
[00153] Technical Validation: Inter-assay Precision
[00154] DNA from remnant laboratory samples from 67 presumably unaffected
individuals,
plus the 27 DNA specimens from Coriell, were analyzed in 3 replication set-
ups. Two negative
controls (a quality control blank [QCB]) and a no-template control [NTC]) were
also included
in each run. Libraries prepared for each run were detected on both the
MiSeq/QSAP and
PGM/Torrent Suite platforms. All variants detected in 3 replication runs from
both the PGM
and MiSeq instruments were verified by manual review using IGV (version
2.3.14). Specimens
failing in 2 or more of the replication runs were excluded from the inter-
assay variability
assessment.
[00155] Fewer verified variants were detected on the PGM/Torrent Suite
platform than on the
MiSeq/QSAP platform, owing to higher assay failure rate on the former (Table
2). The inter-
assay precision was 96.7% for the PGM/Torrent Suite and 99.4% for the
MiSeq/QSAP (Table
2). Of note, discrepant calls detected among the 3 replicates on the
MiSeq/QSAP platform
represented false-positive results; most came from a single sample on a single
replicate, likely
indicating a problem with sample preparation or well contamination.
Table 2. Inter-Assay Concordance of Variant Calls vs. Sanger
PGM/Torrent Suite MiSeq/QSAP
Concordant Calls 1550 2188
- 37 -
CA 02980327 2017-09-19
WO 2016/154584 PCT/US2016/024319
Discrepant Calls 53 13
Total Calls 1603 2201
% Concordance 96.7% 99.4%
Samples analyzed included 27 control DNA specimens with known deleterious
mutations and
67 specimens from volunteers with a total of 352 benign variants.
[00156] Failed Specimens
[00157] Specimen failure was defined as failure to achieve an average coverage
depth of >40x
at any exon. For the MiSeq instrument, there were no failures in replications
1 and 2 and 8
specimen failures in replication 3. Therefore, the overall failure rate was
8.5% (8/94) for
replication 3, or 2.8% (8/282) overall. For the PGM, the failure rate was 9.6%
(9/94) for
replication 1, 13.8% (13/94) for replication 2, and 26.6% (25/94) for
replication 3; the overall
failure rate was 16.7% (47/282). All the failed specimens with low coverage
were among the
control specimens from consented subjects, possibly reflecting higher DNA
quality in the
Coriell DNA samples.
[00158] Four specimens failed in replication 3 on the MiSeq/QSAP platform and
in all 3
replication runs on the PGM/Torrent Suite platform. This finding suggests
specimen quality
issues, although the same specimens were successfully sequenced for all
regions in replications
1 and 2 on the MiSeq/QSAP platform. All the specimens that failed on the
MiSeq/QSAP
platform were from replication 3. The failure rate on the PGM/Torrent Suite
platform was also
highest for replication 3. This points to a sample preparation issue for that
replication, as the
sample libraries for both platforms were prepared together up to and through
the hybrid capture
step.
[00159] Inter-platform Concordance
[00160] As there were more failures in the PGM runs than in the MiSeq runs,
only a subset of
discrepant variant calls from the MiSeq/QSAP platform with calls from the
PGM/Torrent Suite
platform was verified. All 8 discrepant variant calls from MiSeq/QSAP were
from replication 2.
Four of the 8 were similarly observed in replication 2 on the PGM/Torrent
Suite platform. In
addition, 5 of the 8 variant calls were observed in a single sample.
[00161] Analytic Sensitivity: Detection Limits
[00162] Limit of Blank (LOB)
- 38 -
CA 02980327 2017-09-19
WO 2016/154584 PCT/US2016/024319
[00163] The NTC and the QCB bar coded specimens were carried throughout the
assay and
handled identically to all other specimens. The number of reads mapped to the
hg19 genome
sequence was compared to the average aligned reads per sample. For the
MiSeq/QSAP platform
in replication 1, no reads were mapped to the human genome for either the NTC
or the QCB. In
replication 2, the QC blank had no reads but the NTC had 1,486 reads. This
totaled 1.1% of the
average number of reads on the plate and was well below the 20% threshold for
an allele call. In
replication 3, the NTC had 46 reads, representing 0.044% of the average number
of reads in
plate 1.
[00164] For the PGM/Torrent Suite platform, the NTC and QCB demonstrated
0.255% and
0.029% aligned reads in plate 1. In plate 2, the NTC had 9.2% of the average
aligned reads
while the QC blank had zero. The values for the 3rd replication plate were
0.268% and 0.063%
for the NTC and QCB, respectively. The NTC and QCB demonstrated an acceptably
low
overall number of aligned reads on both platforms. The aligned reads were
either not detectable
or well below our cutoff threshold of 20% for variant calls.
[00165] Limit of Detection (LOD)
[00166] The LOD was defined as the lowest DNA concentration (ng/[iL) at which
the average
read depth over the exonic region was maintained at >40 reads per base. To
determine the LOD,
the following experiments can be used. Two Coriell DNA samples, GM14094 and
GM14096,
and a single random DNA sample chosen from the 67 control individuals lacking
pathogenic
BRCA were serially diluted. On the MiSeq/QSAP platform, the control DNAs
failed to achieve
the required average read/coverage depth at 5 ng/[iL demonstrating that the
minimal sample
input (LOD) for the MiSeq/QSAP platform must be greater than 5 ng/[iL (all
shearing reactions
were carried out in 80 [EL volumes). In addition, all variants were
consistently called (i.e., 100%
concordant) at each concentration for the 3 specimens above this lower limit.
On the
PGM/Torrent Suite platform, the samples failed at 5 ng/[iL, demonstrating that
the minimal
sample input must also be greater than 5 ng/[iL (400 ng of DNA). On both
platforms, the 40-bp
and 11-bp deletion mutations were successfully detected at all concentrations.
However, only
99.96% of the called variants were concordant for the non-Coriell control
sample. At 15 ng/[iL,
an insertion was called in the control DNA using the PGM/Torrent Suite
platform that was not
present in any of the other concentrations and was likely due to a sequencing
error.
- 39 -
CA 02980327 2017-09-19
WO 2016/154584 PCT/US2016/024319
[00167] Accuracy
[00168] The 27 DNA specimens obtained from Coriell were included in this
validation study,
in 3 separate runs, on both MiSeq/QSAP and PGM/Torrent Suite platforms. All
previously
known BRCA1 and BRCA2 variants in the specimens were successfully detected by
both
platforms and in all three validation runs (i.e., 100% accuracy for cancer-
associated mutations).
In addition, the overall accuracy of variant calls for the 352 benign sequence
changes detected
in the 67 control samples was determined. There was only one missed call on
the MiSeq/QSAP
platform, which was due to low read depth (coverage). This error could have
been avoided by
adjusting the minimum depth requirement in our QC metric as this was
implemented prior to
going live with the assay. The PGM/Torrent Suite platform yielded two false-
positive calls, one
sequencing error, and 37 missed variant calls, most of which were observed in
only one of the
three validation runs. However, there were 4 variants not called by Ion
Reporter, which were
detected by manual review of the alignment software. Overall, the error rate
was <0.1%
(1/1056) for the MiSeq/QSAP platform and 3.7% (39/1056) for the PGM/Torrent
Suite
platform. With the adjusted QC parameters, the MiSeq/QSAP combination had 100%
sensitivity and nearly 100% specificity. With manual review of all positive
samples, the
MiSeq/QSAP combination also achieved 100% specificity.
[00169] The First 521 Clinical Samples
[00170] For the initial clinical test release, mutation analyses were
performed using both the
MiSeq/QSAP platform and the PGM/Torrent Suite platform variant calling
software. For
samples with discrepant results on the 2 platforms, either the cases were
manually reviewed to
determine the cause of the discrepancy or the samples were retested for
confirmation. There
were 35 discrepancies in the first 521 reported cases, with 34 due to
PGM/Torrent Suite errors.
The single MiSeq/QSAP platform sequencing error was a false-negative result
for a benign
polymorphism. Manual review of the alignment revealed that this was due to a
combination of
strand bias (19% variant) and low coverage. The QC parameters can then be
adjusted to take
advantage of the fact that random shearing allows the filtering of duplicate
reads. The QC
acceptance metric requires that each base in each assay be analyzed from at
least 20
independent reads. This typically resulted in an average depth ranging from
several hundred to a
few thousand. Using adjusted QC parameters, the MiSeq/QSAP combination had
100%
- 40 -
CA 02980327 2017-09-19
WO 2016/154584 PCT/US2016/024319
sensitivity and 100% specificity. For all positive cases, the alignments are
manually reviewed as
a further quality measure.
[00171] After making these adjustments to the QC metrics, the MiSeq/QSAP
platform has
made no further errors in more than 500 consecutive analyses. However, the
PGM/Torrent Suite
combination suffered 2 false-negative results for pathogenic BRCA1 variants: a
10-base pair
insertion and a 64bp deletion. Both of these pathogenic variants were detected
with the
MiSeq/QSAP platform. Figure 4 shows the QSAP alignment for this 64-bp
deletion. Following
this observation the use of the PGM/Torrent Suite platform can be
discontinued. During testing,
to be certain that our new quality metric would ensure the identification of
all variants, all
MiSeq/QSAP analyses were performed in duplicate. Duplication would ensure that
any false-
positives or false- negatives due to strand bias, low coverage, or library
creation would be
detected. In 1006 consecutive duplicate MiSeq/QSAP runs with more than 5000
variants
detected, there were no discrepant results between duplicate analyses (data
not shown).
Therefore, the duplicate run is not required.
[00172] An advantage of NGS platforms over standard Sanger sequencing is their
ability to
determine if 2 SNPs are cis or trans in orientation. If two variants are
captured in a single read
(in this case less than 250 bases), they are revealed as being in cis. If they
are captured on
separate reads, then they are revealed to be in trans. Figure 5 shows an
individual who has two
point mutations in cis. Two such linked variants in the first 521 clinical
samples have been seen.
In addition, in routine operations, the MiSeq/QSAP platform was considerably
more robust than
the PGM/Torrent Suite platform. Accordingly, the PGM/Torrent Suite platform
test can be
discontinued and performing duplicate MiSeq/QSAP runs for each case can be
done to
determine if there are any potential problems with false-positives or false-
negatives due to
library formation.
[00173] There was a single discrepancy between the duplicate MiSeq runs in
noted in the
initial 100 duplicate samples. This was a benign polymorphism that was
detected in one run, but
not detected in the second run. Examination of the sequencing data revealed
that there was
significant strand bias in the second sequencing run leading to 19% a variant
frequency for the
variant. Our QC cut-off at the time was 20%. In order to prevent reoccurrence
of this error, the
QC metric for variant calling was modified. The random fragmentation of the
DNA causes each
-41 -
CA 02980327 2017-09-19
WO 2016/154584 PCT/US2016/024319
individual DNA fragment to have a unique starting and ending nucleotide. This
allows the
bioinformatics to uniquely identify the clones sequenced. The QC metric was
adjusted to
require that each base in every coding exon and 50 base pairs into the exon be
sequenced from
at least 20 different clones. This eliminates errors due to sequencing bias,
since reads from an
overrepresented clone with be ignored, and by requiring a minimum number of
clones to be
sequenced, heterozygotes have close to a 50% representation. After making this
adjustment, no
discrepancies were found in more than 1006 consecutive analyses.
[00174] The data demonstrate that neither the Illumina MiSeq sequencer with
the supplied
MiSeq Reporter software nor the Life Technologies PGM with the supplied
Torrent Suite
software are suitable for clinical laboratory sequencing of BRCA1 and BRCA2.
The MiSeq
system's inability to detect insertions and deletions larger than 9 bp makes
it unacceptable for
BRCA testing, as many of the described deleterious mutations are in that size
range. Similarly,
the inability of the PGM with Torrent Suite software to detect a 10-base pair
insertion and 64-bp
deletion disqualifies that platform from clinical BRCA testing. However, by
combining random
shearing with bait tile capture, the MiSeq platform with the bioinformatics of
the QSAP
alignment and allele calling software, and our quality metrics, the disclosed
assay has 100%
sensitivity and specificity for BRCA1 and BRCA2 sequence variations in our
technical
validation series. Real-world performance may not reach this level of
precision.
[00175] The use of NGS with bait tile exon capture offers several advantages.
First, bait tile
exon capture prior to NGS decreases the likelihood of false-negative results
due to allele drop-
out, which may occur with PCR-based methods when polymorphisms are present in
amplification or sequencing primer sequences. Second, with 5x redundant
tiling, each exon is
captured by multiple baits, further reducing the chance of a false-negative
result due to
individual sequence variation. A third advantage of bait tile capture versus
PCR-based target
enrichment methods is the avoidance of false-positive results due to amplicon
bias in PCR or
library formation. If a base substitution error occurs in an early PCR or
library amplification
cycle, the error will be propagated and result in a mixed population prior to
sequencing. If an
error occurs in a single amplicon, and the amplicon is preferentially
sequenced, this can result in
a false-positive result. With the bait tile capture approach, genomic DNA is
randomly sheared to
fragments of approximately 250 bp prior to bait tile capture. Library
formation occurs after
- 42 -
CA 02980327 2017-09-19
WO 2016/154584 PCT/US2016/024319
capture. Thus, each fragment has different 5 and 3 prime termini, and the
sequence alignment
software can detect if 2 reads are generated from the same fragment. Filters
can be set to only
accept reads from unique fragments, thereby eliminating the possibility of
sequencing errors
due to early PCR or library amplification errors. The selected quality control
metrics require
reads from at least 20 different clones, minimizing the risk of false-positive
sequencing results
in NGS.
[00176] Relative to Sanger sequencing, NGS also has the advantage of detecting
the phase of
SNPs within approximately 250 bp (i.e., the length of sheared genomic DNA
fragments). Since
this technology sequences a single molecule, 2 SNPs that are in cis
orientation will appear
together in the same read; if the orientation is trans, the 2 SNPs will appear
in separate reads.
Sanger sequencing cannot differentiate between cis and trans orientation
without resorting to
family studies.
[00177] In conclusion, described herein is the development and validation of a
rapid, high-
throughput sequencing assay for the detection of BRCA1 and BRCA2 variants
suitable for the
clinical laboratory. Results from the initial 1006 clinical samples tested in
duplicate with the
MiSeq/QSAP combination showed no discrepant variant calls.
[00178] While this specification contains many specific implementation
details, these should
not be construed as limitations on the scope of any inventions or of what may
be claimed, but
rather as descriptions of features specific to particular implementations of
particular inventions.
Certain features described in this specification in the context of separate
implementations can
also be implemented in combination in a single implementation. Conversely,
various features
described in the context of a single implementation can also be implemented in
multiple
implementations separately or in any suitable subcombination. Moreover,
although features may
be described above as acting in certain combinations and even initially
claimed as such, one or
more features from a claimed combination can in some cases be excised from the
combination,
and the claimed combination may be directed to a subcombination or variation
of a
subcombination.
[00179] Similarly, while operations are depicted in the drawings and tables
in a particular
order, this should not be understood as requiring that such operations be
performed in the
particular order shown or in sequential order, or that all illustrated
operations be performed, to
- 43 -
CA 02980327 2017-09-19
WO 2016/154584 PCT/US2016/024319
achieve desirable results. In certain circumstances, multitasking and parallel
processing may be
advantageous. Moreover, the separation of various system components in the
implementations
described above should not be understood as requiring such separation in all
implementations,
and it should be understood that the described program components and systems
can generally
be integrated in a single software product or packaged into multiple software
products.
[00180] Thus, particular implementations of the invention have been described.
Other
implementations are within the scope of the following claims. In some cases,
the actions recited
in the claims can be performed in a different order and still achieve
desirable results. In
addition, the processes depicted in the accompanying figures do not
necessarily require the
particular order shown, or sequential order, to achieve desirable results. In
certain
implementations, multitasking and parallel processing may be advantageous.
- 44 -
